A Randomized Trial Comparing Prednisone with Antithymocyte Globulin/Prednisone as an Initial Systemic Therapy for Moderately Severe Acute Graft-Versus-Host Disease

Louise Cragg, Bruce R. Blazar, Todd Defor, Nikbeel Kolatker, Wesley Miller, John Kersey, Norma Ramsay, Philip McGlave, Alexandra Filipovich, Daniel Weisdorf

Research output: Contribution to journalArticle

97 Scopus citations

Abstract

Glucocorticoids remain the standard approach to initial systemic management of acute graft-versus-host disease (aGVHD). For patients refractory to steroids, antithymocyte globulin (ATG) is frequently used as salvage therapy. We decided to test whether the combination of corticosteroids and equine ATG would improve the outcome of initial management of aGVHD, especially in high-risk patients such as recipients of unrelated donor (URD) transplants. One hundred patients with grade II to IV aGVHD having undergone a related or URD marrow transplant were enrolled in the study. Of the patients, 46 were randomly assigned to therapy with prednisone (60 mg/m2 per day x 7 days) and 50 received ATG/prednisone (15 mg/kg ATG bid plus 20 mg/m2 prednisone bid x 5 days, each followed by an 8-week prednisone taper). An intent-to-treat analysis of the overall response at day 42 revealed equivalent complete plus partial response rates of 76% in both the prednisone and ATG/prednisone therapy groups (P > .80). In univariate analysis, patient age, donor type, site of involvement, or aGVHD stage did not influence overall response to therapy (all P > .2). When treatment arms were studied separately, no single clinical feature predicted outcome in either group. Complications were more frequent in the ATG/prednisone arm; patients experienced more infections with cytomegalovirus (44% versus 22%; P = .02) and more frequent pneumonitis, both infectious and noninfectious (50% versus 24%; P < .01). Epstein-Barr virus lymphoproliferative disease was uncommon (4 cases) and comparable in both arms (P = .35). There was no significant difference in survival at day 100, 6 months, and 2 years between the 2 treatment arms. The more intensive immunosuppressive combination of ATG/prednisone failed to improve control of aGVHD and may have affected survival by causing more infectious complications. Combination therapy with ATG should thus be reserved as second-line therapy in the management of aGVHD.

Original languageEnglish (US)
Pages (from-to)441-447
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume6
Issue number4 A
DOIs
StatePublished - Jan 1 2000

Keywords

  • Acute graft-versus-host disease
  • Antithymocyte globulin
  • Corticosteroids

Fingerprint Dive into the research topics of 'A Randomized Trial Comparing Prednisone with Antithymocyte Globulin/Prednisone as an Initial Systemic Therapy for Moderately Severe Acute Graft-Versus-Host Disease'. Together they form a unique fingerprint.

  • Cite this